Schlenker provided guidance: "For the third quarter 2025, as compared to 1 year prior, we expect revenues before reimbursements to be up in the middle single digits and EBITDA to be 26.75% to 27.75% ...

Scientific consulting firm Exponent (NASDAQ:EXPO) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 19.1% year on year to $147.4 million. Its GAAP profit of $0.49 per ...

Exponent (EXPO) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.30 per share a year ago. These figures are ...

Schlenker provided guidance for the fourth quarter, stating, "We expect revenues before reimbursements to grow in the low to mid-single digits, EBITDA to be 26% to 27% of revenues before ...

Exponent Inc. (EXPO) reported its fourth-quarter 2025 earnings, surpassing analyst expectations with a strong performance in both revenue and earnings per share (EPS). The company posted a quarterly ...

CEO Catherine Corrigan reported "double-digit net revenue growth" for the third quarter, highlighting robust demand for dispute-related work in the energy, transportation, life sciences, and ...

Scientific consulting firm Exponent (NASDAQ:EXPO) reported in Q4 CY2025, with sales up 19.1% year on year to $147.4 million. Its GAAP profit of $0.49 per share was 3.7% above analysts’ consensus ...